Touchdown for HOPE Scheduled for Sunday, February 4, 2018

Mason, OH –The ninth annual Touchdown for HOPE Super Bowl Sunday event will take place Sunday, February 4, 2018, starting with tailgating at 5:30 p.m. and with Super Bowl kick-off at 6:30 p.m., at the Great American Ballpark Champions Club.

Proceeds from Touchdown for HOPE will be used to support Lindner Center of HOPE’s cutting edge research, in addition to providing funding for acquiring new technology for mental health treatment.

The Research Institute at Lindner Center of HOPE has been instrumental in advancing the field of mental health treatment, funds from the event will help support continued efforts. Likewise, technology has the opportunity to advance patient care and improve access, funds from the event will be used to support these initiatives.

Touchdown for HOPE is a classy and fun Super Bowl party with big screen televisions, plush seating, and signature Cincinnati food favorites and other upscale tailgate-style treats. All taking place in a sports fan’s dream location –overlooking the baseball field.  Tickets are $125 per guest, but a young professional’s ticket, for those 35 and under, is priced at $75. Tickets purchased on or before January 15, will receive a discount. Reservations include free parking in Central Riverfront Garage and food and beverages.

Anthony and Dede Muňoz are Honorary Chairs, while Mike Glen is Touchdown Team Captain.

Event details:

Location: Great American Ballpark, Champions Club, 100 Joe Nuxhall Way.

Date: February 4, 2018; 5:30p.m., 6:30 p.m. kick-off

Tickets: $125; $75 young professional’s ticket (Pre-Season prices on or before January 15 are $100 per person and $65 per young professional)

Register on-line at https://lindnercenterofhope.org/donate/touchdown or call 513-536-0328.

A generous list of sponsors makes this event possible. Sponsorship opportunities are still available.

 

Lindner Center of HOPE in Mason is a comprehensive mental health center providing excellent, patient-centered, scientifically-advanced care for individuals suffering with mental illness. A state-of-the-science, mental health center and charter member of the National Network of Depression Centers, the Center provides psychiatric hospitalization and partial hospitalization for individuals age 12-years-old and older, outpatient services for all ages, diagnostic and short-term residential services for adults and adolescents, outpatient services for substance

abuse through HOPE Center North location and co-occurring disorders for adults and research. The Center is enhanced by its partnership with UC Health as its clinicians are ranked among the best providers locally, nationally and internationally. Together Lindner Center of HOPE and UC Health offer a true system of mental health care in the Greater Cincinnati area and across the country. The Center is also affiliated with the University of Cincinnati (UC) College of Medicine.

(l-r) Marjorie Hulgrave, Albert Hulgrave, Frances Lindner and Craig Lindner attended Touchdown for HOPE.

The Research Institute at Lindner Center of HOPE is a site for an open label study with the primary goal of validating a signature (model) based on a panel of serum proteomic markers that discriminate Bipolar I, Bipolar II and Major Depression in people seeking treatment for a major depressive episode. The success of this study could lead to the first diagnostic test that would distinguish between the three mood disorders in a person experiencing depressive symptoms.

Lindner Center of HOPE is seeking a total of 90 study participants, between the ages of 18 and 70, with bipolar I depression, bipolar II depression, or major depression, who are currently depressed. Some exclusions apply, so participants should complete a phone screening.

The study duration is 8 weeks and includes 6 visits and 3 blood draws. Subjects will be paid per visit up to a total of $350.

Call 513-536-0707 for more information. All inquiries are kept confidential.

Study May Provide Information About the Safety and Effectiveness of an Investigational Medication

Individuals struggling with binge eating disorder (B.E.D.) feel that their repetitive overeating is out of control. They may feel embarrassed and guilty after eating an excessive amount of food in a set period of time. This is a disorder and not a decision, yet sufferers often can feel shame.

B.E.D. can have a significant impact on people who are suffering. Research and evaluation of investigational medications could lead to treatments that may reduce suffering.

Those diagnosed with B.E.D. may be eligible for a medical research study. Researchers at Lindner Center of HOPE are currently conducting a medical research study evaluating an investigational medication in adults with B.E.D. In this study, the safety and effectiveness of the investigational medication will be evaluated when it is taken daily for 12 weeks.

Those interested in participating in the study must:

  • Be 18 to 55 years of age.
  • Regularly engage in overeating (binge eating) episodes Study-related tests and investigational medication will be provided to eligible participants at no cost. In addition, reimbursement for travel and related expenses may be provided for completed study visits.

Study-related tests and investigational medication will be provided to eligible participants at no cost. In addition, reimbursement for travel and related expenses may be provided for completed study visits.

Lindner Center of HOPE is one site for this national study seeking to have 300 participants.

Call 513-536-0710 for more information. All inquiries are kept confidential.

 

Touchdown for HOPE Scheduled for Sunday, February 7, 2016

Mason, OH –The seventh annual Touchdown for HOPE Super Bowl Sunday event will take place on February 7, 2016, starting at 6 p.m. with Super Bowl 50 kick-off at 6:30 p.m., at the Great American Ballpark Champions Club.

Once again, proceeds are going to enhance local research being done in Bipolar and Mood Disorders at Lindner Center of HOPE.

“Mood disorders are the most common form of psychiatric illness and are among the leading causes of disability worldwide,” said Dr. Paul E. Keck, Jr., President & CEO of Lindner Center of HOPE. “The study of these devastating illnesses is extremely complex. In spite of the unprecedented growth in the diagnosis of these illnesses, research continues to be under-funded; while much work is still needed to enhance our understanding of these illnesses, the risk factors and the most effective forms of treatment.”

According to Dr. Susan L. McElroy, M.D., Lindner Center of HOPE Chief Research Officer, “ The research occurring in the field right now is extremely exciting. The positive steps we are taking in genetic research and medication development are ones that I never thought I’d live to see.”

Touchdown for HOPE is a classy and fun Super Bowl party with big screen televisions, plush seating, and signature Cincinnati food favorites and other upscale tailgate-style treats. All taking place in a sports fan’s dream location –overlooking the baseball field. Tickets are $125 per guest, but a young professional’s ticket, for those 35 and under, is priced at $75. Tickets include free parking in Central Riverfront Garage and all food and beverages.

Originally conceived in 2010 by Scott Robertson, Carl Satterwhite, John Ryan, Francie Hiltz and Sue Lawrence, this annual event has consistently raised over $200,000 and continues to improve the lives of those suffering with mental illness.

Event details:

Location: Great American Ballpark, Champions Club.
Date: February 7, 2016; 6:00p.m., 6:30 p.m. kick-off
Tickets: $125; $75 young professional’s ticket
Register on-line at https://lindnercenterofhope.org/donate/touchdown or call 513-536-0328.
A generous list of sponsors makes this event possible. Sponsorship opportunities are still available.

By mid-August Lindner Center of HOPE researchers anticipate recruiting for a new medication trial that could impact the treatment of Intermittent Explosive Disorder (IED). IED, characterized by an inability to resist aggressive urges and explosive outbursts, affects six percent of the general population with no designated medications currently available for treatment.

The exploratory Phase II study, expected to begin in mid to late August, has been designed to examine the efficacy, safety and tolerability profile of the novel V1a vasopressin antagonist (SRX246) against placebo, in adults meeting the DSM-5 (Diagnostic and Statistical Manual) criteria for IED. A large body of translational research indicates that blocking the vasopressin (V1a) receptor might be a plausible form of treatment. Studies have found that vasopressin (V1a) has an established role in signaling social and emotional behavior, including aggression.

DSM-5 criteria for IED defines it as recurrent behavioral outbursts representing a failure to control aggressive impulses as manifested by either:

  • Verbal aggression or physical aggression toward property, animals or other individuals, occurring, on average, twice weekly for a period of three months. The physical aggression does not result in damage or destruction of property and does not result in physical injury to animals or other individuals.
  • Three behavioral outbursts involving damage or destruction of property and/or physical assault with physical injury against animals or other individuals occurring within a 12-month period.

The behavior is distressing for the individual and is not premeditated and not due to another psychiatric illness.

“This disorder comes with lots of complications,” according to Dr. Susan McElroy, Chief Research Officer, Lindner Center of HOPE. “Often we see individuals struggling with IED facing legal problems, social issues, marital difficulties, child abuse concerns, medical problems from injuries sustained during the physical outbursts, significant distress, severe psychosocial complications and even loss of employment.”

“The potential for gaining control over IED with medication would be incredibly beneficial for those struggling.”

The clinical trial is seeking to recruit males and females age 18 to 55 with moderate IED. Candidates with substance abuse disorders, compromised medical health or currently taking psychotropic medications will not be eligible to participate. Those meeting criteria should expect to participate in 8 weeks of treatment.

If interested in participating in the trial, contact 513-536-0710.

 

Husband to ride bike from Lindner Center of HOPE to Yellowstone National Park to Memorialize Wife’s Struggle with Depression

Kathy Klausing was loyal and devoted to her family. Sadly, her struggles with depression plagued her until her death in November 2014. Kathy’s husband of 28 years, Jack, misses her every day and wanted to do something to memorialize Kathy. In his mind, a plaque in her honor just wasn’t enough.

“We wanted to do something that would help give hope to others,” said Jack Klausing.

BikeNBagsIIA cycling enthusiast, Jack has decided to ride his bike from Cincinnati, Ohio to Yellowstone National Park, about 2000 miles. Taking it a step farther, Jack has established a fundraiser for Lindner Center of HOPE’s mood disorders research efforts. Kathy spent two-and-a-half weeks at Lindner Center of HOPE in 2013 where she had a positive experience.

Jack and his family believe that raising money to advance the field’s understanding of depression will be a great legacy for Kathy and ideally benefit others who are struggling.

“There is a great deal of misunderstanding about depression. The common thought is people with depression should just get over it. People are afraid to talk about it when someone they know suffers from depression. That person is avoided. This only feeds the sufferer’s negative thoughts,” said Klausing.

Jack and his family have already raised nearly $16,500. Donations can be made directly to Lindner Center of HOPE by mail or online giving at https://webapps2.uc.edu/foundation/LCOH/DonationForm.aspx or through Crowdrise at https://www.crowdrise.com/MilesInMemoryofKathy/fundraiser/jackklausing.

Jack plans to depart on his journey from Lindner Center of HOPE, 4075 Old Western Row Rd., Mason, on Saturday, July 11, 2015 at 9 a.m. The Center is planning a sendoff for him. Jack has established a website and Facebook page so those interested can follow his journey. He also hopes others will be willing to start the conversation about depression and share their journeys.

Media interviews can be arranged with Jack Klausing by coordinating with Jennifer Pierson at 513-536-0316, please call to make arrangements.

Lindner Center of HOPE provides excellent, patient-centered, scientifically-advanced care for individuals suffering with mental illness. A state-of-the-science, mental health center and charter member of the National Network of Depression Centers, the Center provides psychiatric hospitalization and partial hospitalization for individuals age 12-years-old and older, outpatient services for all ages, diagnostic and short-term residential services for adults and adolescents, intensive outpatient program for substance abuse and co-occurring disorders for adults and research. The Center is enhanced by its partnership with UC Health as its clinicians are ranked among the best providers locally, nationally and internationally. Together Lindner Center of HOPE and UC Health offer a true system of mental health care in the Greater Cincinnati area and across the country. The Center is also affiliated with the University of Cincinnati (UC) College of Medicine.

DSC_0022The sixth annual Touchdown for HOPE Super Bowl Sunday event took place on February 1, 2015 at the Great American Ballpark Champions Club. With 423 attendees and $203,000 raised to enhance Bipolar and Mood Disorders Research at Lindner Center of HOPE, The Best Super Bowl Party in Town was a huge success.

Great American Ballpark provided the perfect casual environment, reminiscent of a very large family room, with numerous seating areas and televisions for watching the game, the festivities and the commercials. Guests enjoyed Cincinnati favorite foods including Skyline DSC_0035Chili, Montgomery Inn ribs and Saratoga chips, LaRosa’s pizza, and United Diary Farmers ice cream. As Arizona hosted Super Bowl XLIV, guests  were also treated to a Southwestern menu including, Southwestern Salad, Chicken Empanadas, Pulled Pork Tacos, Steak or Cheese Quesadillas and Churros with dolce de leche, cocoa powder, powdered sugar and cinnamon sugar

“Mood disorders are the most common form of psychiatric illness and are among the DSC_0048leading causes of disability worldwide,” said Dr. Paul E. Keck, Jr., President & CEO of Lindner Center of HOPE. “The study of these devastating illnesses is extremely complex. In spite of the unprecedented growth in the diagnosis of these illnesses, research continues to be under-funded; while much work is still needed to enhance our understanding of these illnesses, the risk factors and the most effective forms of treatment. We are very grateful for the support of Touchdown for HOPE in order to continue to enhance our efforts.”

A generous list of sponsors made this event possible.

 

 

Lindner Center of HOPE’s Chief Research Officer, Dr. Susan McElroy, was recently cited in a Forbes article about her work in the investigation of an experimental drug that could be used in the treatment of depression.

Naurex, a private company founded by a Northwestern University professor in Evanston, Ill., is reporting that this experimental drug works to help push patients out of a major depressive state within 24 hours of getting a single intravenous shot.

Click here to read the Forbes article.

Susan L. McElroy, MD, Chief Research Officer, Lindner Center of HOPE, co-authored study published online by Jama Psychiatry

At some doses, the medication lisdexamfetamine dimesylate, a drug approved to treat attention-deficit/hyperactivity disorder, was effective compared with placebo in decreasing binge-eating (BE) days in patients with binge-eating disorder (BED), a public health problem associated symptoms of mental illness and obesity and for which there are no approved medications, according to a study published online by JAMA Psychiatry.

BED is characterized by recurrent episodes of excessive food consumption accompanied by a sense of loss of control and psychological distress. Cognitive behavioral therapy, as well as psychotherapy, can reduce BE behavior but implementation of these treatments has not been widespread. Consequently, many patients with BED are undertreated despite having functional impairments and difficulties in their social and personal lives. The U.S. Food and Drug Administration has not approved pharmacologic treatments for BED, according to background information in the study.

Susan L. McElroy, MDSusan L. McElroy, M.D., of the Research Institute, Lindner Center of HOPE, Mason, Ohio, and coauthors compared lisdexamfetamine with placebo in adults with moderate to severe BED in a randomized clinical trial from May 2011 through January 2012. The study included 259 and 255 adults with BED in safety and intention-to-treat analyses, respectively. The medication was administered in dosages of 30, 50 or 70 mg/day or placebo.

BE days per week decreased in the 50-mg/d and 70 mg/d treatment groups but not in the 30 mg/d treatment group compared with the placebo group, according to the study results. Results also indicate the percentage of patients who achieved four-week BE cessation was lower with the placebo group (21.3 percent) compared with the 50-mg/d (42.2 percent) and 70-mg/d (50 percent) treatment groups.

“In the primary analysis of this study of adults with moderate to severe BED, lisdexamfetamine dimesylate treatment with 50 and 70 mg/d, but not 30 mg/d, demonstrated a significant decrease (compared with placebo) in weekly BE days per week at week 11. Similarly, BE episodes decreased in the 50- and 70-mg/d treatment groups. The one-week BE episode response status was improved in the 50- and 70-mg/d treatment groups, and a greater proportion of participants achieved four-week cessation of BE episodes and global improvement of symptom severity with all lisdexamfetamine dosages. … Confirmation of these findings in ongoing clinical trials may results in improved pharmacologic treatment for moderate to severe BED,”  the study concludes.

(JAMA Psychiatry. Published online January 14, 2015. doi:10.1001/jamapsychiatry.2014.2162.  at http://media.jamanetwork.com.)

Editor’s Note: Authors made conflict of interest disclosures. This study was supported by Shire Development, LLC, including funding to Scientific Communications & Information and Complete Healthcare Communications, Inc., for support in writing and editing the manuscript. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Susan L. McElroy MD, James I. Hudson MD, ScD, James E. Mitchell MD, Denise Wilfley PhD, M. Celeste Ferreira-Cornwell PhD, Joseph Gao PhD, Jiannong Wang PhD, Timothy Whitaker MD, Jeffrey Jonas MD, Maria Gasior MD, PhD

JAMA Psychiatry. 2015;72(3):-. doi:10.1001/jamapsychiatry.2014.2162

Paul Keck image smallMason, OH, November 19, 2014 – Lindner Center of HOPE’s President and CEO, Dr. Paul E. Keck, Jr., was named amongst Thomson Reuters Highly Cited Researchers, a listing of the world’s leading scholars in the sciences and social sciences, in honor of his landmark contributions to research in the field of Psychiatry/Psychology.

Thomson Reuters, evaluates and recognizes excellence in the scholarly community as demonstrated by the quantitative impact of the sciences by consistently monitoring the undeniable link between citations and influence. Dr. Keck was selected as a Highly Cited Researcher due to the number of citations his work has received from fellow researchers. Essentially, his peers have identified his contributions as being among the most valuable and significant in the field of Psychiatry/Psychology.

The global nature of this study highlights the researchers, institutions and countries on the cutting edge of science, those who are developing innovations that will lead to a brighter tomorrow. The listing of the Highly Cited Researchers was compiled by assessing papers indexed within the Web of Science™ between 2002 and 2012 in 21 broad fields of study. Analysts tracked authors who published numerous articles ranking among the top one percent of the most cited in their respective fields in a given year of publication. View the list and methodology at highlycited.com.

Dr. Keck was also listed in The World’s Most Influential Scientific Minds: 2014. This report is at ScienceWatch.com.

Lindner Center of HOPE provides excellent, patient-centered, scientifically-advanced care for individuals suffering with mental illness. A state-of-the-science, mental health center and charter member of the National Network of Depression Centers, the Center provides psychiatric hospitalization and partial hospitalization for individuals age 12-years-old and older, outpatient services for all ages, diagnostic and short-term residential services for adults and adolescents, intensive outpatient program for substance abuse and co-occurring disorders for adults and research. The Center is enhanced by its partnership with UC Health as its clinicians are ranked among the best providers locally, nationally and internationally. Together Lindner Center of HOPE and UC Health offer a true system of mental health care in the Greater Cincinnati area and across the country. The Center is also affiliated with the University of Cincinnati (UC) College of Medicine.